Medication info

Anabone Injection (Ibandronate Sodium Hydrate)

Prescription medicationInjectionsInjection
Ingredient · strength
Ibandronate Sodium Monohydrate›3.375mg / 1 prefilled syringe
Manufacturer / importer
Aju Pharmaceuticals Co., Ltd.
Appearance
A colorless, transparent solution filled in a colorless, transparent glass prefilled syringe, equipped with a single-use injection needle.
Packaging
3ml/prefilled syringe x 1
Approval status
Active

MFDS item code 201306426 · Approved 2013.03.22 · Insurance code 654004271

Summary

Main use
Treatment of osteoporosis in postmenopausal women
Who receives it
Adults · Children
Adult administration
Inject 3mg intravenously over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D as adjunctive supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible and continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dosage adjustment is required. Patients with renal impairment No dosage adjustment is required for patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or less or whose creatinine clearance is 30ml/min or greater. This drug is not recommended for patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is less than 30ml/min because clinical experience is insufficient. Older adults No dosage adjustment is required.
Child administration
Efficacy and safety have not been studied in children 18 years of age or younger.

Ingredients

Manufacturer
Aju Pharmaceuticals Co., Ltd.

Efficacy & effects

Treatment of osteoporosis in postmenopausal women

  • Osteoporosis in postmenopausal women
View approved original text

Used for the treatment of osteoporosis in postmenopausal women.

How it is given

Adult administration

Inject 3mg intravenously over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D as adjunctive supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible and continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dosage adjustment is required. Patients with renal impairment No dosage adjustment is required for patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or less or whose creatinine clearance is 30ml/min or greater. This drug is not recommended for patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is less than 30ml/min because clinical experience is insufficient. Older adults No dosage adjustment is required.

Child administration

Efficacy and safety have not been studied in children 18 years of age or younger.

Precautions

This medication must only be administered by intravenous injection. Caution is required as injecting into the tissues around arteries or veins may cause tissue damage. Patients with known allergies to this medication or untreated hypocalcemia should not use it. Gastrointestinal symptoms such as gastric inflammation, diarrhea, abdominal pain, dyspepsia, nausea, and constipation may occur during the use of this medication, along with musculoskeletal pain or joint pain, and muscular symptoms. Additionally, symptoms similar to influenza, fatigue, headache, and rashes may occur. Rare side effects such as osteonecrosis of the jaw or external auditory canal have been reported during the use of this medication, thus caution is especially required for cancer patients or those needing dental treatment. If dental treatment is necessary, oral examination prior to treatment is recommended, and excessive dental procedures should be avoided during treatment. This medication can temporarily lower serum calcium levels; therefore, hypocalcemia and any abnormalities in bone and mineral metabolism must be addressed prior to administration. Adequate intake of calcium and vitamin D is important. Patients with impaired renal function or those on medication that may affect the kidneys require regular monitoring and treatment. Severe bone, joint, or muscle pain may occur during the administration of this medication, and if such symptoms appear, consultation with a physician is essential. In addition, pain in the thigh or groin should prompt suspicion of atypical fracture and should be evaluated. Pregnant or breastfeeding women are advised not to use this medication, and safety and efficacy for children under 18 years have not been established. In cases of overdose, liver and kidney function should be carefully monitored, and appropriate treatment should be given if hypocalcemia or hypophosphatemia occurs. This medication should not be mixed with calcium-containing solutions or other intravenous medications and must be diluted with isotonic saline or 5% dextrose solution prior to administration. Used injection needles and syringes must not be reused and should be disposed of in a safe container.

Side effects

  • Gastritis
  • diarrhea
  • abdominal pain
  • dyspepsia
  • nausea
  • constipation
  • musculoskeletal pain
  • joint pain
  • muscle pain
  • influenza-like illnesses
Show 52 more
  • fatigue
  • headache
  • rash
  • bone pain
  • weakness
  • injection site reaction
  • thrombophlebitis
  • venous thromboembolism
  • hypersensitivity reactions
  • angioedema
  • facial swelling
  • edema
  • urticaria
  • uveitis
  • episkleritis
  • scleritis
  • anaphylactic reaction
  • shock
  • exacerbation of asthma
  • Stevens-Johnson syndrome
  • erythema multiforme
  • vesicular dermatitis
  • atypical electronic fracture
  • intertrochanteric femoral fracture
  • external auditory canal osteonecrosis
  • dizziness
  • optic atrophy
  • lower motor neuron lesion
  • tremor
  • nonspecific gastrointestinal disorders
  • benign gastrointestinal neoplasms
  • toothache
  • hyperventilation
  • cough
  • dyspnea
  • laryngitis
  • vaginitis
  • menopausal symptoms
  • multiple organ failure
  • death
  • insomnia
  • anxiety
  • tinnitus
  • hearing loss
  • hypothyroidism
  • lipoma
  • ocular hemorrhage
  • heart failure
  • urinary disorders
  • hematuria
  • skin exfoliation
  • acute renal failure

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to avoid exposure to air and kept at a temperature between 1 to 30 degrees Celsius. Proper storage helps maintain the effectiveness of the medication for a longer time.

Appearance and packaging

Appearance

A colorless, transparent solution filled in a colorless, transparent glass prefilled syringe, equipped with a single-use injection needle.

Package unit

3ml/prefilled syringe x 1

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.